Unlike endpoint‐focused categories, this intermediate state highlights a unique therapeutic opportunity: C3 tumours display high MGMT promoter methylation and are predicted to be temozolomide‐sensitive, suggesting a window for early chemotherapeutic intervention to prevent progression towards aggressive tumour‐driving (C2) or immune‐inflamed (C4) endpoints. The gene discussed is MGMT; the disease is neoplasm.